



August 06, 2025

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: News Release - Unaudited Financial Results for the quarter ended on June 30, 2025.

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No. ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED



Bayer CropScience Limited
Communications
Bayer House, Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
www.bayer.in

News Release

Quarterly Results

Bayer CropScience Limited reports Q1 Results for FY 2025-26

- Revenue from Operations of ₹19,146 million
- Profit Before Tax of ₹3,352 million

Mumbai, August 06, 2025: Bayer CropScience Limited (BSE: 506285) announced today its unaudited results for the first quarter (Q1) of Financial Year (FY) 2025-26. For Q1 ended June 30, 2025, the Company registered Revenue from Operations of ₹19,146 million, compared to ₹16,314 million in the corresponding period of FY 2024-25. Profit Before Tax for the quarter stood at ₹3,352 million, compared to ₹3,158 million in the corresponding quarter of the previous financial year.

Simon Wiebusch, Vice Chairman & Managing Director and CEO, Bayer CropScience Limited, commented on the quarterly results, "In Q1, BCSL achieved 17 percent growth in Revenue from Operations, primarily driven by higher volumes of Corn seeds and Roundup® supported by the early onset of the monsoon. Additionally, we successfully launched BICOTA®, an innovation-backed solution for managing Stem Borers in paddy cultivation nationwide to support our smallholder farmers."

Vinit Jindal, Executive Director and Chief Financial Officer, Bayer CropScience Limited, added, "We delivered a 10 percent increase in Profit After Tax for the quarter, underpinned by strong sales growth and early signs of input cost stabilization. While operating expenses were elevated due to the early onset of the monsoon, our continued focus on cost discipline positions us well for sustained performance."

-END-

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Media Contact:

Snigdha Vishal

Communications, Bayer CropScience Limited

Email: snigdha.vishal@bayer.com



Bayer CropScience Limited
Communications
Bayer House, Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
www.bayer.in

News Release

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.